[go: up one dir, main page]

AR090203A1 - Compuestos heterobiciclicos como inhibidores de pde10 - Google Patents

Compuestos heterobiciclicos como inhibidores de pde10

Info

Publication number
AR090203A1
AR090203A1 ARP130100649A ARP130100649A AR090203A1 AR 090203 A1 AR090203 A1 AR 090203A1 AR P130100649 A ARP130100649 A AR P130100649A AR P130100649 A ARP130100649 A AR P130100649A AR 090203 A1 AR090203 A1 AR 090203A1
Authority
AR
Argentina
Prior art keywords
alq
atoms
independently
saturated
nrara
Prior art date
Application number
ARP130100649A
Other languages
English (en)
Inventor
R Allen Jennifer
Rumfelt Shannon
L Andrews Kristin
Brown James
Chenguang Yuan Chester
M Rzasa Robert
J Chen Jian
Chen Ning
Hu Harrington Essa
Liu Qingyian
Amegadzie Albert
T Nguyen Thomas
J Pickrell Alexander
Qian Wenyuan
Zhong Wenge
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR090203A1 publication Critical patent/AR090203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones que los contienen, y procesos para preparar dichos compuestos. En la presente se proveen también métodos para tratar trastornos o enfermedades que se pueden tratar mediante la inhibición de PDE10, tal como obesidad, diabetes no dependiente de insulina, esquizofrenia, trastorno bipolar, trastorno obsesivo compulsivo, enfermedad de Huntington, y similares. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal farmacéuticamente aceptable, tautómero, o estereoisómero del mismo, donde: cada p y q es en forma independiente 0, 1, 2, 3, 4, 5 ó 6; donde la suma de p y q es 1, 2, 3, 4, 5 ó 6; m es 0, 1, 2, 3 ó 4; A es un anillo heterocíclico de 9 ó 10 miembros de la fórmula (2), donde el grupo -W-T-D< se selecciona del grupo que consiste en: -N=CR⁵-N<; NR⁷-N=C<; -NR⁷-(C=O)-N<; NR⁷-CR⁶R⁷-(C=O)-N<; -NR⁷-(SO₂)-N<; -CR⁵=CR⁵-N<; -CR⁸=N-N<; -CR⁶R⁷-(C=O)-N<; -CR⁶R⁷-NR⁷-(C=O)-N<; -CR⁶R⁷-O-(C=O)-N<; -CR⁶R⁷-(SO₂)-N<; -O-(C=O)-N<; y -O-CR⁶R⁷-(C=O)-N<; J es en forma independiente N o CR³ᶜ; donde cada E, X, Y, y Z son en forma independiente N o CR⁴; donde 0, 1, 2 ó 3 de E, X, Y, y Z son N; (a) cuando J es N, luego G es R¹ o (C=O)R¹; donde R¹ se une a través de carbono; (b) cuando J es CR³ᶜ; luego G es R¹, -NR¹R²; -NH(C=O)R¹; -OR¹, -(C=O)R¹; o -CHR¹R²; donde R¹ se une a través de carbono o nitrógeno; y el anillo que contiene a p y q contiene 0, 1 ó 2 átomos de N y 0, 1 ó 2 átomos de O ó S; R¹ es un anillo monocíclico saturado, parcialmente saturado o insaturado de 5 ó 6 miembros, o un anillo bicíclico saturado, parcialmente saturado o insaturado de 9 ó 10 miembros, unido por carbono o unido por nitrógeno, donde cada uno de dichos anillos contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde cada R¹ en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; R² es en forma independiente H, OH, alq C₁₋₄, un anillo monocíclico saturado, parcialmente saturado o insaturado de 5 ó 6 miembros unido por carbono o unido por nitrógeno, donde cada uno de dichos anillos contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde cada R² alq C₁₋₄ o anillo monocíclico en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; cada R³ᵃ y R³ᶜ es en forma independiente H, F, OH, alq C₁₋₄, o haloalq C₁₋₄; R³ᵇ es en forma independiente F, Cl, Br, CN, OH, O-alq C₁₋₄, alq C₁₋₄, haloalq C₁₋₄, o oxo; R⁴ es halo, R⁴ᵃ, -SR⁴ᵃ, -OR⁴ᵃ, -NHR⁴ᵃ, o -N(alq C₁₋₄)R⁴ᵃ, donde -R⁴ᵃ es H, alq C₁₋₄, un anillo monocíclico saturado, parcialmente saturado o insaturado de 3, 4, 5 ó 6 miembros, donde cada uno de dichos anillos contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde cada R⁴ alq C₁₋₄ o anillo monocíclico en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; cada R⁵ es en forma independiente R⁵ᵃ, -OR⁵ᵇ, -NHR⁵ᵃ, o -N(alq C₁₋₄)R⁵ᵃ, donde R⁵ᵃ es H, alq C₁₋₄, un anillo monocíclico saturado, parcialmente saturado o insaturado de 3, 4, 5 ó 6 miembros, donde cada uno de dichos anillos contiene 0, 1, 2, 3, o 4 átomos de N y 0, 1 ó 2 átomos de O ó S; R⁵ᵇ es alq C₁₋₄, un anillo monocíclico saturado, parcialmente saturado o insaturado de 3, 4, 5 ó 6 miembros, donde cada uno de dichos anillos contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde cada R⁵ alq C₁₋₄ o anillo monocíclico en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; cada R⁶ y R⁷ es en forma independiente H, halo, OH, alq C₁₋₄, O-alq C₁₋₄, un anillo monocíclico saturado, parcialmente saturado o insaturado de 3, 4, 5 ó 6 miembros, donde cada uno de dichos anillos contiene 0, 1, 2, 3, o 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde cada R⁶ y R⁷ alq C₁₋₄ o anillo monocíclico en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; o R⁶ y R⁷ opcionalmente pueden formar un anillo monocíclico saturado o parcialmente saturado de 3, 4, 5 ó 6 miembros, donde cada uno de dichos anillos contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde dicho anillo monocíclico en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; R⁸ es R⁸ᵃ, -O-R⁸ᵃ, -NHR⁸ᵃ, o -N(alq C₁₋₄)R⁸ᵃ, donde R⁸ᵃ es H, alq C₁₋₄, un anillo monocíclico saturado, parcialmente saturado o insaturado de 3, 4, 5 ó 6 miembros, donde cada uno de dichos anillos contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; donde cada R⁸ alq C₁₋₄ o anillo monocíclico en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R⁹; R⁹ es en forma independiente F, Cl, Br, alq C₁₋₆, haloalq C₁₋₄, -ORᵃ, ORᶜ, -O-haloalq C₁₋₄, CN, Rᵇ, Rᶜ, -C(=O)Rᵇ, -C(=O)Rᶜ, -C(=O)ORᵃ, -C(=O)NRᵃRᵃ, -C(=O)NRᵃRᶜ, -C(=NRᵃ)NRᵃRᵃ, -OC(=O)Rᵇ, -OC(=O)NRᵃRᵃ, -O-alq C₁₋₆NRᵃRᵃ, -O-alq C₁₋₆ORᵃ, -SRᵃ, -S(=O)Rᵇ, -S(=O)₂Rᵇ, -S(=O)₂NRᵃRᵃ, -NRᵃRᵃ, -N(Rᵃ)C(=O)Rᵇ, -N(Rᵃ)C(=O)ORᵇ, -N(Rᵃ)C(=O)NRᵃRᵃ, -N(Rᵃ)C(=NRᵃ)NRᵃRᵃ, -N(Rᵃ)S(=O)₂Rᵇ, -N(Rᵃ)S(=O)₂NRᵃRᵃ, -NRᵃalq C₁₋₆NRᵃRᵃ, -NRᵃalq C₁₋₆ORᵃ, -alq C₁₋₆NRᵃRᵃ, -alq C₁₋₆ORᵃ, -alq C₁₋₆N(Rᵃ)C(=O)Rᵇ, -alq C₁₋₆OC(=O)Rᵇ, -alq C₁₋₆C₍₌O₎NRᵃRᵃ, -alq C₁₋₆C₍₌O₎ORᵃ, o oxo; R¹⁰ es halo, alq C₁₋₆, haloalq C₁₋₄, -ORᵃ, -O-haloalq C₁₋₄, CN, -C(=O)Rᵇ, -C(=O)ORᵃ, -C(=O)NRᵃRᵃ, -C(=NRᵃ)NRᵃRᵃ, -OC(=O)Rᵇ, -OC(=O)NRᵃRᵃ, -Oalq C₁₋₆NRᵃRᵃ, -O-alq C₁₋₆ORᵃ, -SRᵃ, -S(=O)Rᵇ, -S(=O)₂Rᵇ, -S(=O)₂NRᵃRᵃ, -NRᵃRᵃ, -N(Rᵃ)C(=O)Rᵇ, -N(Rᵃ)C(=O)ORᵇ, -N(Rᵃ)C(=O)NRᵃRᵃ, -N(Rᵃ)C(=NRᵃ)NRᵃRᵃ, -N(Rᵃ)S(=O)₂Rᵇ, -N(Rᵃ)S(=O)₂NRᵃRᵃ, -NRᵃalq C₁₋₆NRᵃRᵃ, -NRᵃalq C₁₋₆ORᵃ, -alq C₁₋₆NRᵃRᵃ, -alq C₁₋₆ORᵃ, -alq C₁₋₆N(Rᵃ)C(=O)Rᵇ, -alq C₁₋₆OC(=O)Rᵇ, -alq C₁₋₆C₍₌O₎NRᵃRᵃ, -alq C₁₋₆C₍₌O₎ORᵃ, o oxo; Rᵃ es en forma independiente H o Rᵇ; Rᵇ es en forma independiente fenilo, bencilo, o alq C₁₋₆, donde dichos fenilo, bencilo, y alq C₁₋₆ están sustituidos con 0, 1, 2 ó 3 sustituyentes que son alq C₁₋₄, haloalq C₁₋₃, -OH, -O-alq C₁₋₄, -NH₂, -NH-alq C₁₋₄, -OC(=O)alq C₁₋₄, o -N(alq C₁₋₄)alq C₁₋₄; y Rᶜ es en forma independiente un anillo monocíclico saturado, parcialmente saturado o insaturado de 3, 4, 5, 6 ó 7 miembros o un anillo bicíclico saturado, parcialmente saturado o insaturado de 6, 7, 8, 9, 10, 11 ó 12 miembros unido por carbono o unido por nitrógeno, donde dicho anillo contiene 0, 1, 2, 3 ó 4 átomos de N y 0, 1 ó 2 átomos de O ó S; Rᶜ en forma independiente está sustituido con 0, 1, 2 ó 3 grupos R¹⁰.
ARP130100649A 2012-02-29 2013-02-28 Compuestos heterobiciclicos como inhibidores de pde10 AR090203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605148P 2012-02-29 2012-02-29

Publications (1)

Publication Number Publication Date
AR090203A1 true AR090203A1 (es) 2014-10-29

Family

ID=47846219

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100649A AR090203A1 (es) 2012-02-29 2013-02-28 Compuestos heterobiciclicos como inhibidores de pde10

Country Status (10)

Country Link
US (1) US9174992B2 (es)
EP (1) EP2820014A1 (es)
JP (1) JP2015508826A (es)
AR (1) AR090203A1 (es)
AU (1) AU2013225838A1 (es)
CA (1) CA2865980A1 (es)
MX (1) MX2014010377A (es)
TW (1) TW201348231A (es)
UY (1) UY34649A (es)
WO (1) WO2013130890A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
CA2949511A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108430986B (zh) 2015-10-26 2021-08-31 拜耳作物科学股份公司 作为有害生物控制剂的稠合双环杂环衍生物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP7011596B2 (ja) 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
MA46191A (fr) 2016-09-09 2021-04-21 Incyte Corp Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN111051308A (zh) 2017-06-08 2020-04-21 默沙东公司 吡唑并嘧啶pde9抑制剂
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
CA3080959A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
BR112020016466A2 (pt) 2018-02-13 2020-12-15 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição.
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
CA3110113A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
FI3911648T3 (fi) * 2019-01-18 2025-01-10 Astrazeneca Ab 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
EP3696175A1 (en) 2019-02-18 2020-08-19 Syngenta Crop Protection AG Pesticidally active azole-amide compounds
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
ES2953140T3 (es) 2019-03-08 2023-11-08 Syngenta Crop Protection Ag Compuestos de azol-amida activos de manera plaguicida
US20220183294A1 (en) 2019-03-20 2022-06-16 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
US20220306599A1 (en) 2019-03-20 2022-09-29 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
BR112021018822A2 (pt) 2019-03-22 2021-11-23 Syngenta Crop Protection Ag Derivados de n-[1-(5-bromo-2-pirimidin-2-il-1,2,4-triazol-3-il)etil]-2-ciclopropil-6-(trifluorometil)piridina-4-carboxamida e compostos relacionados como inseticidas
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
TWI853009B (zh) 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物
EP3953343A1 (en) 2019-04-11 2022-02-16 Syngenta Crop Protection AG Pesticidally active diazine-amide compounds
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
CA3195127A1 (en) * 2020-10-16 2022-05-05 John K. Walker Rev-erb agonists
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
EP4074712A1 (en) 2021-04-13 2022-10-19 Siegfried AG Process for the synthesis of 1,3-dihydro-imidazo[4,5-b]pyridin-2-one and/or derivatives thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN118239959A (zh) * 2022-12-23 2024-06-25 上海深势唯思科技有限责任公司 环丙烷类tlr7和8抑制剂及其制备方法和用途
WO2025132870A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Intellectual Property (No.4) Limited Chemical compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU701127B2 (en) 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
ES2223588T3 (es) * 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
ES2322158T3 (es) * 2001-04-18 2009-06-17 Euro-Celtique S.A. Derivados 1-(4-piperidinil)-1,3-dihidro-2h-indol-2-ona y compuestos afines como analogos de la nociceptina y ligandos del orl-1 para el tratamiento del dolor.
SE0300456D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2605899C (en) * 2005-04-26 2011-02-08 Pfizer Limited Triazole derivatives as vasopressin antagonists
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
CA2643044A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
US8093257B2 (en) 2007-05-04 2012-01-10 Bristol-Myers Squibb Company [6,5]-bicyclic GPR119 G protein-coupled receptor agonists
US20110118286A1 (en) 2008-07-16 2011-05-19 Santhosh Francis Neelamkavil Bicyclic heterocycle derivatives and their use as gpcr modulators
US20120016119A1 (en) * 2009-01-22 2012-01-19 Yasunori Tsuboi NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND
AU2010294209A1 (en) * 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
AU2011253143A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
MX2012013130A (es) * 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.
WO2011145718A1 (ja) * 2010-05-21 2011-11-24 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
JP2012020973A (ja) * 2010-07-15 2012-02-02 Mitsubishi Tanabe Pharma Corp 医薬組成物
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CN102617548A (zh) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用

Also Published As

Publication number Publication date
EP2820014A1 (en) 2015-01-07
US9174992B2 (en) 2015-11-03
TW201348231A (zh) 2013-12-01
AU2013225838A1 (en) 2014-09-11
JP2015508826A (ja) 2015-03-23
WO2013130890A1 (en) 2013-09-06
CA2865980A1 (en) 2013-09-06
UY34649A (es) 2013-09-30
MX2014010377A (es) 2014-10-23
US20130225552A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
AR090203A1 (es) Compuestos heterobiciclicos como inhibidores de pde10
PE20211050A1 (es) Inhibidores de ptpn11
CO2019000686A2 (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
AR090005A1 (es) Imidazo[1,2-a]pirimidinas y piridinas sustituidas
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR091781A1 (es) Antagonistas del receptor de 5-ht3
AR087628A1 (es) Inhibidores de pde10 de pirimidina
AR111242A1 (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
PE20141791A1 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR107928A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
AR110405A1 (es) Compuestos
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR095347A1 (es) Compuestos orgánicos
AR099138A1 (es) Piridinas fusionadas como inhibidores del complejo p97
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR091490A1 (es) Antagonistas de iap
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
AR098871A1 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure